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Abstract 
Ubiquitination of proteins is a post-translational modification which decides on the cellular fate of the 
protein. Addition of ubiquitin moieties to proteins is carried out by the sequential action of 3 enzyme: 
E1-activating enzyme, E2-conjugating enzyme and E3 ubiquitin ligase. The TRAF-interacting protein 
(TRAIP, TRIP, RNF206) functions as RING-type E3 ubiquitin ligase but its physiological substrates 
are not yet known. TRAIP was reported to interact with TRAF (tumor necrosis factor (TNF) receptor-
associated factors) and the two tumor suppressors CYLD and Syk (spleen tyrosine kinase). Ectopically 
expressed TRAIP was shown to inhibit nuclear factor-kappa B (NF-κB) signaling. However, recent 
results suggested a role for TRAIP in biological processes other than NF-κB regulation. Knock-down 
of TRAIP in human epidermal keratinocytes repressed cellular proliferation and induced a block in the 
G1/S phase of the cell cycle without affecting NF-κB signaling. TRAIP is necessary for embryonal 
development since mutations affecting the Drosophila homolog of TRAIP are maternal effect-lethal 
mutants and TRAIP knock-out mice die in utero due to aberrant regulation of cell proliferation and 
apoptosis. These findings underline the tight link between TRAIP and cell proliferation. In this review, 
we summarize the data on TRAIP and put them into a larger perspective regarding a role of TRAIP in 
the control of tissue homeostasis. 
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Ubiquitination of proteins  
Ubiquitination, a conserved post-translational protein modification regulating the cellular fate of 
proteins, is involved in multiple biological functions such as proliferation, differentiation, apoptosis, or 
inflammation (1,2). Ubiquitins are covalently attached to lysine residues of target proteins or to a pre-
existing ubiquitin chain through the sequential action of the E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzyme and E3 ubiquitin-ligase (Fig. 1). During mono-ubiquitination, the C-
terminal glycine of one ubiquitin monomer is attached  to one lysine residue in target proteins. During 
multi-ubiquitination, several ubiquitins are attached to different lysines in target proteins. During poly-
ubiquitination, additional ubiquitin monomers are attached to one of the seven lysines (K) (K6, K11, 
K27, K29, K33, K48, K63) or the N-terminal methionine (M1) of the existing ubiquitin unit; thus 
generating polymers which have different structures and flexibilities (3,4). These ubiquitin signals are 
recognized by proteins carrying ubiquitin-binding domains and which decide on the cellular fate and 
function of ubiquitinated proteins (3-9). However, this simplistic view has been challenged by findings 
that the cellular metabolism of selected proteins does not always follow these paradigms (6). Recently, 
the formation of linear head-to-tail polyubiquitin chains (10) and there in vivo relevance for 
controlling inflammation and immune signaling (11-16) has been demonstrated. The physiological 
process of protein ubiquitination can be reversed by deubiquitinases (Fig. 1) which remove ubiquitin 
conjugates (17). 
During the ubiquitination process, an ubiquitin monomer is activated in an ATP-dependent manner by 
an E1 ubiquitin-activating enzyme and subsequently transferred to an E2 ubiquitin-conjugating 
enzyme. Ubiquitin-charged E2 interacts with E3 ubiquitin ligases which determine the substrate 
specificity of the ubiquitination reaction (18). E3 ligases are classified into two major families: HECT 
(homologous to the E6-AP carboxyl-terminus)-type and RING (Really Interesting New Gene)-type E3 
ligases (19). HECT-type E3 ligases function as true ubiquitination catalysts since the activated 
ubiquitin is covalently bound via a thioester bond to a conserved cysteine within the HECT domain 
before transfer to the substrate. In contrast, RING-type E3 ligases do not covalently bind ubiquitin but 
serve as a scaffold to bring the E2 and the substrate into close proximity to facilitate the ubiquitin 
transfer (20,21). The RING domain, highly conserved in eucaryotes, is composed of 40 to 60 amino 
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acids that are arranged in a “cross-brace” or interleaved manner C-X2-C-X9-39-C-X1-3-H-X2-3-
(N/C/H)-X2-C-X4-48-C-X2-C around two zinc ions (Zn
2+
) (20). RING domains seem to be engaged 
exclusively in the recruitment and positioning of the E2 conjugating enzymes for allowing substrate 
ubiquitination (20,22,23). RING domain E3 ubiquitin ligases function either as single subunit or 
multisubunit proteins (20). Numerous RING variants have been described where cysteines and 
histidines swapped their positions or where aspartates or asparagines replaced cysteines to coordinate 
zinc ions (20). However, some of these variants, i.e. the LIM (Lin-11, Isl-1, Mec-3) (24) and the PHD 
(Plant Homology Domain) (25) domains fold differently and do not catalyze ubiquitination (20). The 
U-Box domain proteins, in which the zinc-binding amino acids are replaced with charged and polar 
residues forming hydrogen-bonds to stabilize the structure, have E3 ubiquitin ligase activity involved 
in quality control of intracellular proteins (26,27). 
The knowledge about E3 ubiquitin ligase partner proteins (substrates and E2 enzymes) is extremely 
important to understand their physiological functions. However, the identification of molecular 
partners of E3 ligases is hampered by the inefficiency of biochemical screens due to low substrate 
levels and intrinsically weak interactions between E3s and their substrates (28,29), leading to the 
paucity of confirmed functional interactions. 
 
The molecular structure and evolution of TRAIP protein 
The E3 ubiquitin ligase TRAF-interacting protein TRAIP was identified as interactor of TRAF, and 
ectopically expressed TRAIP was shown to inhibit tumor necrosis factor-alpha (TNFα)-mediated NF-
B activation (30). TRAIP is a 53kDa protein that contains a 55 amino acids long RING domain at its 
N-terminal end which is followed by a putative coiled-coil domain and a leucine-zipper region (Fig. 
2). The RING domain of TRAIP is of the Cys3His2Cys3 (RING-H2) type. The Cys and His residues 
are highly conserved and serve to bind two functionally essential zinc ions. RING domains share a 
conserved 3-dimensional structure constituted principally of four elements built around the Cys/His 
residues: an N-loop, a first β-sheet region, a βα-region, and a C-loop (31). These structural conserved 
regions provide a scaffold to spatially position four hydrophobic and two polar residues which are 
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crucial for RING-E3 function. The second and third hydrophobic amino acids contribute to the 
hydrophobic core, while the two remaining hydrophobic and the two polar residues directly participate 
through hydrophobic and electrostatic interactions in E2/RING-E3 binding (31). The four hydrophobic 
(I9, F29, L34, P47) and two polar (Q36 and R50) amino acids (numbers refer to human TRAIP, 
Genebank NP_005870) have been highly conserved in the evolution of TRAIP proteins. In-vitro 
ubiquitination experiments suggested that TRAIP has the ability to undergo auto-ubiquitination, an 
activity that was dependent on an intact RING domain. Therefore, TRAIP can be considered at least in 
vitro as functional ubiquitin ligase (32). Until now, no validated in vivo substrates of TRAIP have 
been identified. Two publications reporting on large scale yeast two-hybrid screens to identify human 
E2/E3 interactions mentioned several TRAIP/E2 pairs which were not further validated by functional 
assays (33,34). 
Structure prediction analysis (psiPRED V 3.0; (35)) of human TRAIP protein showed a high 
proportion of long α-helices in the region of amino acids 60 to 270 while only short α-helical 
structures and β-sheets were predicted for the remaining parts. The long α-helical structures 
correspond to the coiled-coil and leucine zipper region proposed previously (30) which are structural 
motives most likely implicated in protein-protein and/or protein-DNA interactions (36-38). These two 
regions of TRAIP are the only ones required to interact with the TRAF domain of TRAF1 or 2 in yeast 
two-hybrid assays (30).  
The N-terminal region encompassing the RING, coiled-coil and leucine zipper domains of human 
TRAIP has 90, 68 or 28% sequence identity with TRAIP orthologues from mouse, Xenopus laevis or 
Drosophila melanogaster, respectively (Fig. 2). The conservation level is even higher for RING 
domain amino acids which are important for Zn
2+
 binding and E2 interaction (see above). While the 
conservation of the C-terminal half of TRAIP, which does not contain any known protein motif, is 
quite good for vertebrate proteins (68% for human vs. mouse; 37% for human vs. Xenopus), the C-
terminal sequences of human and Drosophila TRAIP have practically no sequence identity anymore. 
There are two stretches (35 and 14 amino acids long) outside of the RING domain which share high 
sequence identities from H. sapiens to Xenopus (Fig. 2), indicating that they might be functionally 
important for TRAIP. The variable degree of sequence similarity for the domains of the TRAIP 
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protein suggests that the evolutionary pressure for sequence conservation has been varying. This might 
indicate that, except for the RING domain, these regions do not necessarily have similar functions in 
different species, i.e. substrates might be different. 
 
Transcriptional regulation of the TRAIP gene 
The human and mouse TRAIP genes are located on chromosome 3 and 9, respectively. Both genes 
have 15 exons and a total length of 20-30kbp. Annotation analysis of the human gene predicted 11 
alternatively spliced transcripts (ENSEMBL data base and Havana project). Six of them do not encode 
proteins, four transcripts translate into proteins for which there is no experimental evidence so far that 
they are expressed in vivo. The longest transcript encodes the 53 kDa TRAIP protein, Little is known 
about the transcriptional regulation of the gene or the organization of its promoter. Microarray analysis 
revealed that TRAIP mRNA level was significantly upregulated 4 hours after treatment of human 
acute monocytic leukemia cells with lipopolysaccharides (39). The authors postulated a NF-B site 
1736bp upstream of the initiator ATG site without presenting experimental evidence. Similarly, 
TAp63α, a homologue of p53, upregulated TRAIP expression in Hep3B hepatoma cell line (40). 
Putative p53 binding sites were found in intron 1 by transcription factor binding site analysis. Small-
hairpin RNA-mediated downregulation of β-catenin expression in a gastric cancer cell line suppressed 
cell proliferation and induced apoptosis. Microarray analysis revealed that TRAIP expression was 
reduced by more than 3-fold in β-catenin knockdown cells (41). Analysis of the 5’upstream sequence 
from the human TRAIP gene predicted a conserved E2F transcription factor binding site close to the 
transcription start site (42). This would be consistent with a report that an E2F repressor complex 
binds to the TRAIP gene promoter in serum-deprived T98G cells (43). 
 
Identification of TRAIP interactors and their roles in molecular signaling pathways 
a) TRAF proteins 
TRAIP was identified to interact with the TRAF domain (amino acids 183-409) from TRAF1 in a 
yeast two-hybrid screen using a mouse thymocyte cDNA library (30). Subsequently, it was shown that 
GST-TRAIP transfected into human embryonic kidney 293 cells coprecipitated overexpressed TRAF1, 
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TRAF2, TRAF3, TRAF5 and TRAF6 (30,32). The coiled–coil and leucine zipper domains of TRAIP 
(amino acids 56-270) provide the full interaction with the TRAF domain of TRAF1 and TRAF2 (30) 
(Fig. 2). Glutathione-S-transferase pull-down experiments showed that TRAIP is recruited to the 
cytoplasmic domains of TNFR2 and CD30 receptors only in the presence of TRAF2 (30). 
Overexpression of TRAIP in 293 cells inhibited NF-κB activation mediated by TRAF2 and TNFα (30) 
and interleukin IL-1 (44). In contrast to this, stable expression of TRAIP in L929 mouse fibroblasts 
did not negatively regulate TNFα- or IL-1-mediated phosphorylation of IBα (inhibitor of NF-κB 
alpha) (32). Furthermore, stable retroviral expression of TRAIP in the murine monocytic cell line 
RAW264.7 failed to repress phosphorylation of IBα upon RANKL (Receptor Activator for NF-κB 
Ligand) treatment (32). However, expression of higher TRAIP levels in 293T cells was able to 
suppress RANKL-mediated NF-B activation (45). These findings evoke the question whether 
inhibition of NF-B signaling is not an experimental artifact rather than a physiological function of 
TRAIP. Interestingly, ectopic expression of mutant TRAIP composed of the coiled-coil and the 
leucine zipper only inhibited TRAF2-mediated NF-B activation (30) as strongly as the full-length 
protein, suggesting that only TRAIP domains interacting with TRAF2 but not the RING domain are 
required for inhibition. Although it is difficult to compare the expression level of TRAIP from the 
different experiments, the observed discrepancies could be explained by presuming that only 
artificially high but not physiological amounts of TRAIP are capable to perturb the interaction 
between TRAFs and TNFR family members and to inhibit NF-B signaling. The majority of 
endogenously and ectopically expressed C-terminally tagged TRAIP is localized to the nucleolus in 
breast epithelial cell lines (46). Regarding TRAIP/TRAF interaction, this would be inconsistent with 
the subcellular localization of TRAF proteins which are mainly found at the cell membrane and/or in 
the cytosol (47). 
Several groups reported findings on the effect of either knock-down or overexpression of TRAIP on 
TNFα-induced cell death. Mouse embryonic fibroblasts (NIH3T3 cells) transfected with siRNA 
targeting TRAIP showed a marked dose-dependent induction of activated caspase-3 and a significant 
reduction in cell viability following TNFα/cycloheximide treatment (48). These findings suggested 
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that mouse TRAIP prevents TNFα/cycloheximide-mediated apoptosis. Without showing the data, the 
authors claimed that TNF-induced cell death was not affected by overexpression of TRAIP in NIH3T3 
cells. TNFα-induced activation of caspase-8 in MCF7 breast cancer cells was decreased upon knock-
down of TRAIP (46). Overexpression of TRAIP led to the loss of viable, adherent MCF7 cells in 
response to TNFα addition (46), similarly to a report that overexpression of TRAIP enhanced TNF-
mediated cell death in HeLa cells (30). In the immortalized mouse hypothalamic N42 cell line, TRAIP 
knockdown promoted TNFα-induced NF-B activity, decreased cell death and increased the 
expression of B-cell lymphoma 2 (Bcl2) mRNA (49). 
 
b) CYLD 
Yeast two-hybrid assays and coimmunoprecipitation in mammalian cells demonstrated that the C-
terminal part of TRAIP interacts with the tumor suppressor CYLD (44). Mutational inactivation of the 
CYLD gene causes the formation of skin appendage tumors (Brooke-Spiegler Syndrome) such as 
cylindromas, trichoepitheliomas and spiradenomas (50). CYLD protein functions as K63-specific 
deubiquitinase that negatively regulates NF-B (44,51-53), Jun N-terminal Kinase (JNK) (54) and β-
catenin (55) signaling. Moreover, recombinant CYLD cleaved in vitro K63- and linear-linked but not 
K48-linked tetraubiquitin chains suggesting that CYLD prefers ubiquitin substrates adopting an open 
conformation (56). In keratinocytes, CYLD inhibits by deubiquitination the translocation of the proto-
oncogene Bcl-3 into the nucleus, thus preventing the transcription of cyclin D1 and cell proliferation 
(57). TPA and UV activate CYLD in primary keratinocytes and augment the repressive interaction of 
CYLD with HDAC6 leading to increased levels of acetylated α-tubulin (58). CYLD binds through its 
CAP-Gly domains to acetylated α-tubulin in the perinuclear region of cells where CYLD negatively 
affects Bcl-3 nuclear entry (58). Mutational inactivation of the CYLD gene in Brooke-Spiegler 
Syndrome patients permits increased cyclin D1 transcription due to higher nuclear levels of Bcl-3. 
Interestingly, CYLD KO mice have no spontaneous skin phenotype but develop significantly higher 
number of and larger papillomas than wildtype or heterozygous mice after treatment with DMBA and 
TPA (57). In addition to this, three groups have reported on the implication of CYLD in the regulation 
of cell proliferation and mitosis (58-60), which is of interest in the light of our results regarding the 
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effect of TRAIP depletion on proliferation (see below) and their physical interaction (44). Whether 
this interaction means that CYLD and TRAIP control the ubiquitination levels of each other or of 
common substrates remains to be seen but this information will be crucial to understand their 
biological functions. With respect to the fate of common substrates, the linkage type of the ubiquitin 
chains formed by TRAIP would be important to know since CYLD appears to be specific for K63- or 
linear-linked ubiquitin chains. In vitro ubiquitination assays with bacterially purified protein showed 
that TRAIP undergoes autoubiquitination in the presence of UbcH5 but not with a range of other E2 
proteins (32). However, UbcH5 is well known for its ability to promote autoubiquitination of 
numerous E3 ligases without being necessarily physiologically relevant. Furthermore, it is difficult to 
predict whether TRAIP works as K48 or K63 E3 ligase since UbcH5 has the capacity to introduce 
different linkage types, depending on the partner E3 ligase (20).  
 
c) Syk 
A yeast two-hybrid screen identified TRAIP as binding partner of spleen tyrosine kinase Syk, a non-
receptor protein kinase which is thought to act as tumor suppressor in melanoma and breast cancer 
(46,61-63). Syk enhances the TNFα-dependent activation of NF-B (64), an effect that is reversed by 
overexpressed TRAIP. TNFα activates Syk by phosphorylation at tyrosine residues promoting its 
binding to TRAIP (46). TRAIP becomes phosphorylated after binding of activated Syk (46). 
Ectopically co-expressed TRAIP and Syk in breast cell cancer lines co-localized in cytosolic punctate 
complexes in a small percentage of cells (46). TNFα increased the level of punctate complexes 
suggesting that Syk, previously reported to shuttle between the cytoplasma and the nucleus (65), might 
facilitate the nuclear export of TRAIP. 
Interestingly, none of these described interactors has been reported to be ubiquitinated by TRAIP. 
 
Implications of TRAIP in proliferation and differentiation 
a) Mammalian cells 
TRAIP is expressed at low levels in a large number of adult tissues such as intestine, lung, brain, skin, 
testes, thymus and spleen (30,66). The TRAIP mRNA level is strongly decreased in normal human 
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epidermal primary keratinocytes undergoing differentiation induced by high calcium concentration, 
high cell density or short phorbol ester treatment (42). TRAIP expression was decreased in the 
immortalized monocytic mouse cell line (RAW 264.7) induced to undergo differentiation 
(osteoclastogenesis) (32), and in mouse T lymphocytes upon stimulation with anti-TCR and anti-
CD28 antibodies (30), suggesting that its expression is down-regulated in differentiating cells. In 
addition, TRAIP expression was described as a specific target of the mammalian target of rapamycin 
(mTOR) (42) signaling, a protein kinase regulating cell growth and starvation (67). In addition, mTOR 
inhibits autophagy, a conserved lysosomal degradation pathway which is highly active during tissue 
differentiation and organism development (68). Activation of autophagy was recently proposed to 
control the morphological reorganization occurring in human keratinocytes during the early steps of 
differentiation (69), indicating that mTOR-dependent-TRAIP-expression could be implicated in the 
regulation of the balance between proliferation and differentiation in keratinocytes, and perhaps in 
other cells. 
Knock-down of TRAIP by lentiviral-transduced shRNAs in proliferating primary keratinocytes 
resulted in strong inhibition of cell proliferation and cell-cycle arrest in the G1/S phase (42). The 
morphology of keratinocytes after TRAIP knock-down was reminiscent of differentiated cells, 
consistent with increased expression of the differentiation markers keratin 1 and profilaggrin (42). 
However, TRAIP knock-down in keratinocytes was not accompanied by an increase in NF-B activity 
at 72 hours post-transduction (42). Interestingly, TRAIP is required for early mice development since 
homozygous TRAIP knock-out mice died in utero at embryonic day 6.5/7.5 due to the failure to 
develop primitive embryonic tissues (48). This was consistent with decreased number of proliferative 
cells and excessive apoptosis in TRAIP-/- embryos (48).  
 
b) NOPO, the Drosophila homologue of TRAIP 
In a screen for cell cycle regulators, a Drosophila maternal effect-lethal mutant was identified that 
affected the ‘no poles’ (NOPO) gene (CG5140) (70). The nopo gene encodes a protein containing an 
N-terminal RING domain that has a 47% sequence identity with the RING domain of human TRAIP 
and an overall sequence identity of 20% (70). One of the mutant nopo alleles had a glutamic acid to 
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lysine change at position 11 in the RING domain of NOPO protein, a residue that is highly conserved 
(invariantly aspartic or glutamic acid) in TRAIP homologues. Mutant nopo embryos undergo mitotic 
arrest during the rapid S-M cycles of syncytial embryogenesis showing barrel-shaped acentrosomal 
mitotic spindles as most prominent feature (70). The authors proposed that NOPO is required for the 
preservation of genomic integrity during early embryogenesis (70). Absence of NOPO leads to the 
activation of a CHK2-mediated DNA checkpoint which causes mitotic arrest (70). Interestingly, co-
expressed Drosophila NOPO and human TRAIP localized to nuclear punctae in interphase HeLa cells, 
underscoring their functional homology (70). Most likely, the nuclear punctae correspond to nucleoli 
since both endogenous and ectopically expressed TRAIP has been reported to be nucleolar in 
mammalian cell lines (46). In a high-throughput yeast two-hybrid screen (71), NOPO interacted with 
the E2 enzyme Bendless (BEN), the Drosophila homolog of yeast Ubc13 (72,73) and human UBE2N. 
Using yeast two-hybrid assays the interaction was confirmed using BEN as bait and shown to be 
abolished using either NOPO RING domain or BEN mutants (70). Drosophila BEN mutants have 
nopo-like defects (70) indicating that NOPO and BEN are functionally connected. BEN expressed in 
HeLa cells was found throughout the cells with a predominantly perinuclear staining; however, when 
co-expressed with TRAIP a large proportion of cells showed expression of BEN in nuclear punctae 
co-localized with TRAIP (70). These data suggest that TRAIP and BEN can interact, and therefore, 
one would expect that homologues of BEN would do similarly. However, bacterially purified TRAIP 
was not ubiquitinated in vitro by Ubc13/Uev1A (32). In addition, UBE2N was not identified as human 
TRAIP-binding protein in two large yeast two-hybrid screens (33,34). It remains to be seen whether 
the functional failure of TRAIP/Ubc13 autoubiquitination is due to species differences, to missing 
partner molecules, i.e. CYLD or Syk, or to the use of an in vitro assay where posttranslational 
modifications such as phosphorylation, important for some E2/E3 interactions, are missing.  
Recently, it has been reported that NOPO modulates the Egr (Eiger, Drosophila TNF ortholog)-
induced JNK-independent cell death in Drosophila through the transcriptional upregulation of two pro-
apoptotic genes, reaper and hid (74). Genetic engineering experiments further showed that complex 
formation between NOPO and Ben/dUEV1a is required for NOPO-induced apoptosis.  
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These results indicate that TRAIP is tightly implicated in the regulation of cellular proliferation and 
survival consistent with the finding that TRAIP expression is down-regulated when cells leave the cell 
cycle and undergo differentiation. Putative substrates of TRAIP-mediated ubiquitination might 
therefore be involved in the control of cell cycle progression and cell cycle exit/differentiation. The 
balance between cell proliferation and growth arrest/differentiation in epidermis must be tightly 
controlled to ensure tissue homeostasis. Notch and p63 signaling pathways are important effectors 
governing epidermal stratification and differentiation after keratinocytes switched from symmetric to 
asymmetric cell divisions (75-77). It remains to be elucidated whether and how TRAIP affects these 
signaling pathways. 
 
TRAIP and the nucleolus 
As mentioned above, TRAIP is mainly found in the nucleolus in primary cells and cell lines. The 
nucleolus is a major nuclear substructure which has prominent functions in the synthesis of 
components required for the formation of ribosomes, and which impinges on the control of numerous 
cellular processes (78-81). Proteome studies showed that the nucleolus is a dynamic structure whose 
composition varies during the cell cycle and in response to metabolic conditions (82). Signals for 
nucleolar sequestration and release of proteins are ill defined and no consensus nucleolar localization 
sequence has been identified. It has been proposed that protein nucleolar localization may result from 
high-affinity interaction of specific regions with nucleolar building blocks such as rDNA, rRNA or 
protein components (83). Several motifs that can target proteins to the nucleolus are composed mostly 
of Arg and Lys residues ranging in size from 7 to about 30 amino acids (84,85). Inspection of the 
TRAIP amino acid sequence revealed several regions, mainly in the C-terminal part of the protein, 
which are moderately enriched in basic amino acids. Furthermore, in silico analysis of TRAIP did not 
identify nuclear localization sequences, well characterized and moderately conserved motifs 
predictable by suitable algorithms (86). Cellular localization studies of truncated TRAIP proteins are 
required to delineate the region(s) responsible for nuclear and nucleolar import. In addition, to fully 
understand the biological function of TRAIP it will be necessary to determine the impact of its knock-
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down or forced expression on the structure and function of the nucleolus and to investigate the cellular 
fate of TRAIP after nucleolus disassembly during cell mitosis.  
 
TRAIP in human diseases  
As shown above, TRAIP interacts with CYLD and Syk which are tumor suppressors implicated in the 
formation of skin appendages tumors such as cylindroma, trichoepithelioma and spiradenoma for 
CYLD (50,87) and of melanomas and breast tumors for both CYLD and Syk (61-63,88,89). 
Interestingly, TRAIP expression is increased in basal cell carcinomas (42) and in multiple breast 
epithelial cell lines with oncogenic potentials ranging from nonmalignant to highly invasive (46) 
whereas, concomitantly, the tumor suppressor expression levels are decreased in basal cell carcinomas 
(CYLD) (90) and in breast epithelial cell lines (CYLD and Syk) (46,88). Thus, the question whether 
TRAIP plays a direct pathogenic role in tumorigenesis and whether CYLD and/or Syk suppress 
aberrant cell proliferation by controlling TRAIP activity through deubiquitination and/or 
phosphorylation are topics for future research. 
A two-stage candidate gene association study of chromosome 3p21 with inflammatory bowel disease 
demonstrated an association between a single nucleotide polymorphism (SNP) in an intron of the 
human TRAIP gene and Crohn's disease (91). Because of the localization of this SNP in the 3’non-
translated region of the gene the authors argue that TRAIP is unlikely to play an important role in 
disease pathogenesis but may be in linkage disequilibrium with two nonsynonymous SNPs in the 
macrophage stimulating 1 receptor gene. Furthermore, an association analysis of 3p21 with Crohn's 
disease using SNPs in the New Zealand population excluded TRAIP as candidate gene (92). 
Nevertheless, differential gene expression analysis showed a decrease of TRAIP gene expression in 
Crohn’s disease patients (93).  
 
Conclusions 
The initially described interaction of TRAIP with TRAF proteins and the ensuing negative regulation 
of NF-B signaling seem to be caused by the non-physiological binding of over-expressed TRAIP to 
the C-terminal region of TRAF proteins. Both the C-terminal part of TRAF proteins (TRAF domain) 
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and the region of TRAIP protein identified to bind TRAF form coiled-coils, secondary structure 
elements well known to provide protein-protein interactions. In fact, coiled-coils have been 
specifically used to engineer proteins so that they can interact with non-physiological partner proteins 
(94). Furthermore, the finding that suppression of TRAIP expression in keratinocytes did not increase 
the basal NF-B activity (42) provided strong evidence that the physiological roles of TRAIP extend 
beyond the regulation of NF-B activity. 
Based on recently published data in keratinocytes (42) and the finding that TRAIP expression is down-
regulated when cells leave the cell cycle and undergo differentiation in other cell types (30,32) we 
conclude that the E3 ubiquitin ligase TRAIP is required for cellular proliferation, most likely by 
controlling cell cycle progression from G1 to S. The two TRAIP-interacting tumor supressors CYLD 
and Syk negatively affect cellular proliferation which may suggest that all three act together to 
regulate various physiological processes as depicted in Fig. 3. Whether CYLD or Syk activity changes 
both TRAIP posttranslational modifications such as ubiquitination or phosphorylation and/or 
indirectly gene expression is a central question to understand the biological function of TRAIP. 
Another important challenge in the future will be the identification of proteins that are ubiquitinated 
by TRAIP and the E2 enzyme(s) collaborating with TRAIP. Identification of bona fide substrates of 
TRAIP will be rather difficult using current methodology due to the inherent weak interaction of most 
E3 ubiquitin ligases with their substrates. None of the currently available methods appears to work in a 
general and predictable way, so that several biochemical and genetically approaches will probably be 
required to identify TRAIP substrates. 
The development of mouse models ectopically expressing TRAIP or in which TRAIP expression is 
ablated will be required to confirm the results obtained by in vitro experiments and to define more 
precisely physiological pathways that depend on TRAIP. Due to the embryonic lethality of TRAIP 
knock-out mice (48), inducible systems are required to study the effects of TRAIP ablation in different 
tissues. Efforts to generate these animals are underway in the laboratory. Combining the results of 
these approaches should improve our understanding of cell cycle control and may deliver new 
opportunities for therapeutic interventions in human diseases such as tumor formation. 
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Figure Legends 
 
Figure 1: Ubiquitin is activated in an ATP-dependant manner by the ubiquitin-activating enzyme E1. 
Activated ubiquitin is transferred to an ubiquitin-conjugating enzyme E2 and subsequently to an 
ubiquitin ligase E3 which catalyzes the transfer of ubiquitin to a lysine residue of the substrate (mono-
ubiquitination). Linkage of additional ubiquitins either to different lysines of the substrate or to lysines 
(K6, K11, K27, K29, K33, K48 or K63) of the already attached ubiquitin monomer produces multi-
ubiquitinated or poly-ubiquitinated proteins, respectively. Ubiquitin moieties can be removed in a 
reverse process carried out by deubiquitinating enzymes (DUB). 
 
Figure 2: Schematic diagram of TRAIP showing the positions of the RING-finger, coiled-coil region 
and leucine zipper domains and locations of binding sites for TRAF proteins, and CYLD and SYK. 
The numbers below the domains indicate the percentage of sequence identity of mouse TRAIP 
(mTRAIP), Xenopus (xTRAIP) and Drosophila melanogaster homolog of TRAIP (dTRAIP) with 
human TRAIP (hTRAIP). The double arrows indicate regions with high sequence identities in 
vertebrate TRAIPs. The following GenBank sequences were used: hTRAIP NP_005870.2; mTRAIP 
NP_035764.2; xTRAIP NP_001084838.1; and dTRAIP NP-611305.1. Coiled-coil and leucine zipper 
domain annotations were based on predictive analysis of TRAIP sequences using the following 
programs: COILS version 2.2 (95), Paircoil2 (96) and 2ZIP (97).  
 
Figure 3: The scheme illustrates the relationship of TRAIP with CYLD, Syk and TRAFs and the 
different cellular processes these TRAIP interactors impinge on. Double arrows means that the two 
proteins interact but that it is not yet clear in which way the activity of the partner protein is regulated. 
The following abbreviations have been used: NF-B, nuclear factor κB; NFAT, nuclear factor of 
activated T cells; PI3K, phosphoinositide-3 kinase; PKC, protein kinase C; DAG, diacylglycerol; 
MAPK, mitogen activated protein kinase, PLCγ, phospholipase Cγ; PLK1, polo-like kinase 1; 
HDAC6, histone deacetylase 6; Bcl-3, B-cell lymphoma 3 protein. 
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